<DOC>
	<DOCNO>NCT02438345</DOCNO>
	<brief_summary>PRO 140 2102 multicenter , randomize , double-blind , placebo-controlled , clinical trial observe systemic , long-acting , anti-HIV treatment monoclonal CCR5 antibody ( PRO 140 ) adjunct new , optimize , oral antiretroviral regimen HIV-infected injection drug user viral rebound document poor adherence previous antiretroviral regimen . Eligible subject ( approximately 76 ) randomize 1:1 receive optimize background antiretroviral regimen ( OBR ) plus supervised weekly subcutaneous treatment either PRO 140 placebo . Blood sample safety efficacy variable obtain 24 week duration study . Safety monitor throughout course study .</brief_summary>
	<brief_title>PRO 140 Human Immunodeficiency Virus</brief_title>
	<detailed_description />
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<criteria>1 . Exclusive CCR5tropic virus determine determine Enhanced Sensitivity Trofile™ HIV Tropism Assay 2 . Males female , age ≥ 18 year 3 . Screening plasma HIV1 RNA &gt; 1,000 copies/mL confirm second test current antiretroviral regimen 4 . History nonprescription injection and/or noninjection recreational drug use 5 . CD4 lymphocyte cell count &gt; 100 cells/mm3 6 . Clinically normal rest 12lead ECG screen visit 7 . Women reproductive potential must negative serum pregnancy test Late Screening Visit . Within hour prior receive first dose study drug , woman reproductive potential must negative urine pregnancy test . Male female subject must agree participate conception process agree use one barrier method contraception plus one highly reliable contraceptive method early screening visit week 24 . 8 . Nonadherent , history poor adherence previous antiretroviral regimen . 1 . CXCR4tropic virus , dual/mixed tropic ( R5X4 ) virus determine Enhanced Sensitivity Trofile™ HIV Tropism Assay 2 . Females pregnant , lactating , breastfeeding , plan become pregnant study 3 . Diagnosis acute viral hepatitis ( define active infection hepatitis A new diagnosis hepatitis B C within 24 week dose ) 4 . Prior use entry , attachment , CCR5 coreceptor , fusion inhibitor , include PRO 140 , experimental approve 5 . Participation experimental drug trial ( ) within 30 day early screen visit study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>